Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

Mariona Riudavets; Benjamin Wyplosz; Maria Rosa Ghigna; Angela Botticella; Pamela Abdayem; Pauline Pradere; Ines Kasraoui; Charles Roux; Cécile Le Pechoux; Camilo Garcia; David Planchard

doi:10.1016/j.jtocrr.2022.100319

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

Mariona Riudavets, Benjamin Wyplosz, Maria Rosa Ghigna, Angela Botticella, Pamela Abdayem, Pauline Pradere, Ines Kasraoui, Charles Roux, Cécile Le Pechoux, Camilo Garcia, David Planchard

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The use of immune checkpoint inhibitors (ICIs) has drastically transformed the therapeutic landscape in lung cancer. Special focus has been put on immune-related toxicity; however, infections can also seem during ICI treatment. Although rare, tuberculosis (TB) has been increasingly identified after ICIs, and it seems that the programmed cell death protein 1 and programmed death-ligand 1 pathway is directly involved in its pathophysiology. Here, we describe the case of a patient with advanced NSCLC who developed abdominal TB after 32 months of pembrolizumab and who remains in tumor remission 10 months after discontinuation of this drug. Routine screening for latent TB before ICI treatment is advised, with closer collaboration between infectious disease specialists and oncologists.

Original language	English
Article number	100319
Journal	JTO Clinical and Research Reports
Volume	3
Issue number	5
DOIs	https://doi.org/10.1016/j.jtocrr.2022.100319
Publication status	Published - 1 May 2022

Keywords

Case report
Immune-checkpoint inhibitors
Non–small cell lung cancer
Tuberculosis

Access to Document

10.1016/j.jtocrr.2022.100319

Cite this

Riudavets, M., Wyplosz, B., Ghigna, M. R., Botticella, A., Abdayem, P., Pradere, P., Kasraoui, I., Roux, C., Le Pechoux, C., Garcia, C., & Planchard, D. (2022). Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report. JTO Clinical and Research Reports, 3(5), Article 100319. https://doi.org/10.1016/j.jtocrr.2022.100319

@article{1b0dbfe3010848469e631980ea869ed4,

title = "Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report",

abstract = "The use of immune checkpoint inhibitors (ICIs) has drastically transformed the therapeutic landscape in lung cancer. Special focus has been put on immune-related toxicity; however, infections can also seem during ICI treatment. Although rare, tuberculosis (TB) has been increasingly identified after ICIs, and it seems that the programmed cell death protein 1 and programmed death-ligand 1 pathway is directly involved in its pathophysiology. Here, we describe the case of a patient with advanced NSCLC who developed abdominal TB after 32 months of pembrolizumab and who remains in tumor remission 10 months after discontinuation of this drug. Routine screening for latent TB before ICI treatment is advised, with closer collaboration between infectious disease specialists and oncologists.",

keywords = "Case report, Immune-checkpoint inhibitors, Non–small cell lung cancer, Tuberculosis",

author = "Mariona Riudavets and Benjamin Wyplosz and Ghigna, {Maria Rosa} and Angela Botticella and Pamela Abdayem and Pauline Pradere and Ines Kasraoui and Charles Roux and {Le Pechoux}, C{\'e}cile and Camilo Garcia and David Planchard",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = may,

day = "1",

doi = "10.1016/j.jtocrr.2022.100319",

language = "English",

volume = "3",

journal = "JTO Clinical and Research Reports",

issn = "2666-3643",

number = "5",

}

Riudavets, M, Wyplosz, B, Ghigna, MR, Botticella, A, Abdayem, P, Pradere, P, Kasraoui, I, Roux, C, Le Pechoux, C, Garcia, C & Planchard, D 2022, 'Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report', JTO Clinical and Research Reports, vol. 3, no. 5, 100319. https://doi.org/10.1016/j.jtocrr.2022.100319

TY - JOUR

T1 - Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab

T2 - A Case Report

AU - Riudavets, Mariona

AU - Wyplosz, Benjamin

AU - Ghigna, Maria Rosa

AU - Botticella, Angela

AU - Abdayem, Pamela

AU - Pradere, Pauline

AU - Kasraoui, Ines

AU - Roux, Charles

AU - Le Pechoux, Cécile

AU - Garcia, Camilo

AU - Planchard, David

PY - 2022/5/1

Y1 - 2022/5/1

N2 - The use of immune checkpoint inhibitors (ICIs) has drastically transformed the therapeutic landscape in lung cancer. Special focus has been put on immune-related toxicity; however, infections can also seem during ICI treatment. Although rare, tuberculosis (TB) has been increasingly identified after ICIs, and it seems that the programmed cell death protein 1 and programmed death-ligand 1 pathway is directly involved in its pathophysiology. Here, we describe the case of a patient with advanced NSCLC who developed abdominal TB after 32 months of pembrolizumab and who remains in tumor remission 10 months after discontinuation of this drug. Routine screening for latent TB before ICI treatment is advised, with closer collaboration between infectious disease specialists and oncologists.

AB - The use of immune checkpoint inhibitors (ICIs) has drastically transformed the therapeutic landscape in lung cancer. Special focus has been put on immune-related toxicity; however, infections can also seem during ICI treatment. Although rare, tuberculosis (TB) has been increasingly identified after ICIs, and it seems that the programmed cell death protein 1 and programmed death-ligand 1 pathway is directly involved in its pathophysiology. Here, we describe the case of a patient with advanced NSCLC who developed abdominal TB after 32 months of pembrolizumab and who remains in tumor remission 10 months after discontinuation of this drug. Routine screening for latent TB before ICI treatment is advised, with closer collaboration between infectious disease specialists and oncologists.

KW - Case report

KW - Immune-checkpoint inhibitors

KW - Non–small cell lung cancer

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85128990753&partnerID=8YFLogxK

U2 - 10.1016/j.jtocrr.2022.100319

DO - 10.1016/j.jtocrr.2022.100319

M3 - Article

AN - SCOPUS:85128990753

SN - 2666-3643

VL - 3

JO - JTO Clinical and Research Reports

JF - JTO Clinical and Research Reports

IS - 5

M1 - 100319

ER -

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

Abstract

Keywords

Access to Document

Other files and links

Cite this